Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1–Expressing Esophageal Squamous Cell Carcinoma
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.00057 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Guo Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guo Yu, PhD, and Na Zhang, BM, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; Ai-Jia Guan, BM, Firs…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guo Yu, PhD, and Na Zhang, BM, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; Ai-Jia Guan, BM, First Clinical Medical College, Southern Medical University, Guangzhou, Ch…
ORCID-Profile: Guo Yu, Ai-Jia Guan, Guo-Fu Li
Zitieren
APA
Yu, G., Zhang, N., Guan, A. J., Qiao, Y. W., & Li, G. F. (2023). Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1–Expressing Esophageal Squamous Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00057
Vancouver
Yu G, Zhang N, Guan AJ, Qiao YW, Li GF. Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1–Expressing Esophageal Squamous Cell Carcinoma. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00057
BibTeX
@article{Yu2023,
author = {Yu, Guo and Zhang, Na and Guan, Ai-Jia and Qiao, Yu-Wei and Li, Guo-Fu},
title = {Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1–Expressing Esophageal Squamous Cell Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.00057}
}
EUVIMED